ENDRA Life Sciences Inc. filed its 10-K on Mar 16, 2023 for the period ending Dec 31, 2022. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2897 USD | -0.48% | -4.07% | -86.33% |
05-14 | Transcript : ENDRA Life Sciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-10 | ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.33% | 3.2M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+48.43% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- NDRA Stock
- News ENDRA Life Sciences Inc.
- ENDRA Life Sciences Inc. Auditor Raises 'Going Concern' Doubt